High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death
High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death
复制标题
DOI：
10.1007/s00428-011-1084-z
复制
发表时间：
2011-06-01
期刊：
影响因子：
3.5
通讯作者：
Thalmann, George N.
中科院分区：
文献类型：
--
作者：
Fleischmann, Achim;Rocha, Carla;Thalmann, George N.
淋巴结阳性前列腺癌患者是一个重要的队列，其危险因素定义不明确。CD 10是一种细胞表面金属肽酶，已被认为在前列腺癌进展中发挥作用。使用由原发性肿瘤和淋巴结转移构建的组织微阵列评估了119例淋巴结阳性前列腺癌患者的CD 10表达。所有患者均行根治性乳腺癌切除术和标准化扩大淋巴结清扫术。他们没有新辅助治疗，并接受了延期雄激素剥夺。在原发性肿瘤中，与低CD 10表达相比，高CD 10表达与疾病早期死亡显著相关（5年生存率73.7% vs. 91.8%; p = 0.043）。在转移瘤中，CD 10高表达与较大的转移瘤总大小显著相关（中位数11.4 vs. 6.5 mm; p = 0.015），早期疾病死亡（5年生存率71.5% vs. 87.3%; p = 0.017）和全因死亡（5年生存率70.0% vs. 87.2%; p = 0.001）。转移瘤中的CD 10表达增加了对总生存期的独立预后信息（p = 0.029），在对原发肿瘤的Gleason评分、淋巴结肿瘤负荷和切除边缘进行校正后。总之，前列腺癌中CD 10的高表达预示着早期死亡。这些信息是原发性肿瘤和淋巴结转移所固有的，可能有助于个性化患者管理。
Patients with nodal positive prostate cancers are an important cohort with poorly defined risk factors. CD10 is a cell surface metallopeptidase that has been suggested to play a role in prostate cancer progression. CD10 expression was evaluated in 119 nodal positive prostate cancer patients using tissue microarrays constructed from primary tumors and lymph node metastases. All patients underwent radical prostatectomy and standardized extended lymphadenectomy. They had no neoadjuvant therapy and received deferred androgen deprivation. In the primary tumor, high CD10 expression was significantly associated with earlier death from disease when compared with low CD10 expression (5-year survival 73.7% vs. 91.8%; p = 0.043). In the metastases, a high CD10 expression was significantly associated with larger total size of metastases (median 11.4 vs. 6.5 mm; p = 0.015), earlier death of disease (5-year survival 71.5% vs. 87.3%; p = 0.017), and death of any cause (5-year survival 70.0% vs. 87.2%; p = 0.001) when compared with low CD10 expression. CD10 expression in the metastases added independent prognostic information for overall survival (p = 0.029) after adjustment for Gleason score of the primary tumor, nodal tumor burden, and resection margins. In conclusion, a high CD10 expression in prostate cancer predicts early death. This information is inherent in the primary tumors and in the lymph node metastases and might help to personalize patient management.